Idiopathic Short Stature Clinical Trial
Official title:
A 12-month, Open-labelled, Randomised, Parallel-group, Multi-centre, Interventional Trial to Evaluate the Efficacy and Safety of Recombinant Human Growth Hormone (hGH) (Norditropin® Nordilet®) Therapy on Height Velocity (Ht-V) in Patients With Idiopathic Short Stature in Korea
Verified date | November 2015 |
Source | Novo Nordisk A/S |
Contact | n/a |
Is FDA regulated | No |
Health authority | South Korea: Korea Food and Drug Administration (KFDA) |
Study type | Interventional |
This trial is conducted in Asia. The aim of this trial is to evaluate the efficacy and safety of recombinant human growth hormone (hGH) in subjects with idiopathic short stature in Korea.
Status | Completed |
Enrollment | 54 |
Est. completion date | December 2014 |
Est. primary completion date | December 2014 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 4 Years to 11 Years |
Eligibility |
Inclusion Criteria: - Informed consent obtained from subject's parents or legally acceptable representative before any trial-related activities. (Trial-related activities are any procedure that would not have been performed during normal management of the subject.) - Pre-pubertal status (males aged from 4 to 11 [both inclusive], females aged from 4 to 9 [both inclusive]): an absence of breast development in females (Tanner 1 only) and testicular volume below 4 mL in males - Growth hormone level above 10 ng/mL following a stimulation test (test result within 6 months from screening can be used) - Height below 3 percentile - Bone age below or equal to 12 year - Epiphyses confirmed as open in patients at least 10 years or more of age Exclusion Criteria: - Known presence of one or more pituitary hormone deficiencies (ACTH (adrenocorticotropic hormone), ADH (antidiuretic hormone), FSH (follicle-stimulating hormone), LH (luteinising hormone), TSH (thyroid-stimulating hormone)) - Known primary hypothyroidism, adrenal insufficiency or hypogonadism (treated or untreated) - Specific types of growth failure including, but not limited to, known chromosomal abnormalities associated with growth failure and altered sensitivity to growth hormone - Bone age is advanced over chronological age more than 3 years - Active malignancy, CNS (central nervous system) trauma, active chemotherapy or radiation therapy for neoplasia - Prior history of intracranial hypertension - Hypertrophic cardiomyopathy |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Novo Nordisk A/S |
Korea, Republic of,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Height velocity (Ht-V) | After 6 months of treatment | No | |
Secondary | Change in Ht-SDS (height standard deviation score) | From day 0 to the end of treatment (month 6) | No | |
Secondary | Change in IGF related factors: IGF-I (insulin-like growth factor-I) | From day 0 to the end of treatment (month 6) | No | |
Secondary | Change in IGF related factors: IGFBP-3 (insulin-like growth factor binding protein-3) | From day 0 to the end of treatment (month 6) | No | |
Secondary | Change for bone age | From day 0 to the end of treatment (month 6) | No | |
Secondary | Occurrence of Adverse events | From day 0 through month 6 | No | |
Secondary | Ht-V (height velocity) | At the first 6 months and the last 6 months of group A | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT06382155 -
A Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature
|
Phase 2 | |
Recruiting |
NCT05894876 -
A Study of the Genetic Basis of Response to Growth Hormone Treatment in Children With Idiopathic Short Stature
|
||
Completed |
NCT01246219 -
Short Stature Related Distress
|
Phase 4 | |
Completed |
NCT00965484 -
Genotropin Study Assessing Use of Injection Pen
|
Phase 3 | |
Completed |
NCT00710307 -
Epidemiology Study on Insulin-like Growth Factor-1 in Children With Idiopathic Short Stature (EPIGROW Study)
|
||
Completed |
NCT01248416 -
Aromatase Inhibitors, Alone And In Combination With Growth Hormone In Adolescent Boys With Idiopathic Short Stature
|
Phase 3 | |
Completed |
NCT01504802 -
Pharmacodynamics of CNP During Growth Hormone Treatment
|
N/A | |
Completed |
NCT00488124 -
Growth Response in Short Children Suffering From a Disease With Growth Retardation and Treated With Somatropin
|
Phase 2 | |
Withdrawn |
NCT01438801 -
Predictive Value of the Insulin-like Growth Factor-1 (IGF-1) Generation Test for the Growth Response to Growth Hormone Treatment (PRED-IGF)
|
Phase 4 | |
Recruiting |
NCT06309979 -
A Study to Assess Growth in Children With Idiopathic Short Stature
|
||
Terminated |
NCT00121875 -
Study to Identify Markers of Insulin Resistance During Growth Hormone Treatment for Short Stature
|
Phase 4 | |
Not yet recruiting |
NCT05858606 -
Multidisciplinary Evaluation and a Genome-wide Analysis in a Cohort of Idiopathic Short Stature Patients
|
N/A | |
Active, not recruiting |
NCT04020913 -
Skeletal Muscle Effects of GH in Boys
|
||
Completed |
NCT01401244 -
Bioequivalence of Two Somatropin Products (Norditropin® Versus Genotropin®) in Healthy Adult Volunteers
|
Phase 1 | |
Recruiting |
NCT02973061 -
The Impact of the Use of Recombinant Human Growth Hormone on ADHD Characteristics in Children and Adolescents
|
||
Recruiting |
NCT01604395 -
Long-term Safety and Effectiveness of Growth Hormone With GHD, TS, CRF, SGA , ISS and PWS in Children
|
||
Active, not recruiting |
NCT00840944 -
A 4 Year Combination Therapy of Growth Hormone and (GnRH) Agonist in Children With a Short Predicted Height
|
Phase 4 | |
Completed |
NCT01070173 -
Ghrelin Levels in Children With Poor Growth
|
N/A | |
Completed |
NCT01543867 -
Safety and Efficacy of Long-term Somatropin Treatment in Children
|
N/A | |
Recruiting |
NCT04798690 -
Long-term Safety and Effectiveness of Growtropin®-II Treatment in Children With Short Stature
|